Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Sun A. | - |
dc.contributor.author | Han, Byoung G. | - |
dc.contributor.author | Kim, Sung G. | - |
dc.contributor.author | Han, Sang Y. | - |
dc.contributor.author | Jo, Young I. | - |
dc.contributor.author | Jeong, Kyung H. | - |
dc.contributor.author | Oh, Kook H. | - |
dc.contributor.author | Park, Hyeong C. | - |
dc.contributor.author | Park, Sun H. | - |
dc.contributor.author | Kang, Shin W. | - |
dc.contributor.author | Na, Ki R. | - |
dc.contributor.author | Kang, Sun W. | - |
dc.contributor.author | Kim, Nam H. | - |
dc.contributor.author | Jang, Young H. | - |
dc.contributor.author | Shin, Seong H. | - |
dc.contributor.author | Cha, Dae R. | - |
dc.date.accessioned | 2021-09-03T08:08:30Z | - |
dc.date.available | 2021-09-03T08:08:30Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-04 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84073 | - |
dc.description.abstract | Aims: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). Methods: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. Results: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m(2)). At Week 12, the adjusted mean change +/- standard error in HbA1c with gemigliptin was -0.82% +/- 0.14% (-8.9 +/- 1.5 mmol/mol), whereas it was 0.38% +/- 0.14% (4.2 +/- 1.5 mmol/mol) with placebo (significant between-group difference, P < .001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, -0.3 kg; placebo, -0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (-41.9 mg/g creatinine, P = .03) and macroalbuminuria (-528.9 mg/g creatinine, P < .001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). Conclusions: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject | GLYCATED PROTEIN PARAMETERS | - |
dc.subject | CHRONIC KIDNEY-DISEASE | - |
dc.subject | ADVANCED NEPHROPATHY | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | LINAGLIPTIN | - |
dc.subject | SITAGLIPTIN | - |
dc.subject | HEMOGLOBIN | - |
dc.subject | DEATH | - |
dc.subject | COMPLICATIONS | - |
dc.title | Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, Dae R. | - |
dc.identifier.doi | 10.1111/dom.12863 | - |
dc.identifier.scopusid | 2-s2.0-85013467019 | - |
dc.identifier.wosid | 000396614700014 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, v.19, no.4, pp.590 - 598 | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.citation.title | DIABETES OBESITY & METABOLISM | - |
dc.citation.volume | 19 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 590 | - |
dc.citation.endPage | 598 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject.keywordPlus | GLYCATED PROTEIN PARAMETERS | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | ADVANCED NEPHROPATHY | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | LINAGLIPTIN | - |
dc.subject.keywordPlus | SITAGLIPTIN | - |
dc.subject.keywordPlus | HEMOGLOBIN | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordAuthor | diabetic nephropathy | - |
dc.subject.keywordAuthor | DPP-IV inhibitor | - |
dc.subject.keywordAuthor | phase III study | - |
dc.subject.keywordAuthor | type 2 diabetes mellitus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.